Talazoparib Exposure‐Efficacy Analysis in Patients With Advanced Breast Cancer and GermlineBRCA1/2Mutations in the EMBRACA Trial

Autor:	Jennifer K. Litton, Akos Czibere, Yanke Yu, Jenny Zheng, Mohamed Elmeliegy, Diane D. Wang, Iulia Cristina Tudor
Rok vydání:	2020
Předmět:	Adult Oncology medicine.medical_specialty Time Factors Maximum Tolerated Dose medicine.medical_treatment Genes BRCA2 Genes BRCA1 Antineoplastic Agents Breast Neoplasms Poly(ADP-ribose) Polymerase Inhibitors 030226 pharmacology & pharmacy 03 medical and health sciences 0302 clinical medicine Breast cancer Internal medicine medicine Humans Pharmacology (medical) Progression-free survival Germ-Line Mutation Aged Proportional Hazards Models Aged 80 and over Pharmacology Chemotherapy Dose-Response Relationship Drug business.industry Hazard ratio BRCA mutation Cancer Middle Aged medicine.disease Progression-Free Survival Confidence interval Treatment Outcome 030220 oncology & carcinogenesis PARP inhibitor Phthalazines Female business
Zdroj:	The Journal of Clinical Pharmacology. 60:1324-1333
ISSN:	1552-4604 0091-2700
DOI:	10.1002/jcph.1623
Popis:	In the phase 3 EMBRACA trial, treatment with the poly(ADP-ribose) polymerase inhibitor, talazoparib, led to significantly improved progression-free survival (PFS) compared with chemotherapy (hazard ratio, 0.54; 95% confidence interval, 0.41-0.71; P.0001). We conducted an exposure-efficacy analysis using EMBRACA data from 285 patients who were treated with talazoparib and had available pharmacokinetic parameters to evaluate the effect of talazoparib exposure (time-varying average talazoparib concentration [C
Databáze:	OpenAIRE
Externí odkaz:	https://explore.openaire.eu/search/publication?articleId=doi_dedup___::673fef0b2c79733a9de4307ea8246304 https://doi.org/10.1002/jcph.1623 Zobrazit plný text záznamu Plný text